GET DAILY SIGNALSCommunity Health Systems (CYH) Swings to Q3 Loss as Revenues Drop 10.7% and Guidance Is Cut
Key Takeaways
- Community Health Systems (CYH) posted a net loss attributable to stockholders of $86 million, or $0.63 per share, in the third quarter of 2026, compared with net income of $130 million, or $0.96 per share, a year earlier.
- Adjusted EPS came in at a loss of $0.48, missing the consensus estimate of roughly a $0.29 loss.
- Net operating revenues declined 10.7% year over year to $2.76 billion, below the approximately $2.80 billion analysts had projected.
- Same-store revenues increased 3.8%, with same-store admissions up 2.2% and adjusted admissions up 3.6%, showing that core operations performed better than the reported headline figures.
- Adjusted EBITDA fell 25.5% to $280 million, reflecting divestitures, an unfavorable payer mix, and higher medical specialist fees.
- The company reduced its full-year 2026 outlook for revenue, adjusted EBITDA, and loss per share.
- Additional detail is available on the company’s dedicated pages covering major news, price moves, price targets, and forecasts.
Earnings Context and Why It Matters
Community Health Systems (CYH) remains one of the largest hospital operators in the country and has been reshaping its portfolio through divestitures while navigating cost pressures. This quarter’s report is useful because it shows how the remaining same-store facilities are performing as divested hospitals drop out of the top line. The results also shed light on payer-mix trends, specialist fee inflation, and supplemental reimbursement costs. Following a narrower loss in the second quarter, these figures help clarify whether management’s expectations for a stronger second half are on track.
Reported Results
For the third quarter ended September 30, 2026, Community Health Systems (CYH) recorded a net loss attributable to stockholders of $86 million, or $0.63 per share, versus net income of $130 million, or $0.96 per share, in the same period last year. On an adjusted basis, the company posted a loss of $0.48 per share compared with earnings of $1.27 per share a year earlier, falling short of the consensus estimate of roughly a $0.29 loss.
Net operating revenues declined 10.7% to $2.76 billion from $3.09 billion, missing the roughly $2.80 billion consensus forecast. The drop was driven mainly by divestitures, although same-store revenue rose 3.8% on the back of 2.2% growth in same-store admissions and 3.6% growth in adjusted admissions. Adjusted EBITDA decreased 25.5% to $280 million from $376 million, pressured by an unfavorable payer mix, lower non-patient revenue, and higher medical specialist fees along with supplemental reimbursement program expenses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Shares fell roughly 12% in after-hours trading after the release. The revenue and adjusted EPS misses, together with the downward revision to full-year guidance, appeared to outweigh the positive same-store trends. Investor sentiment had already been cautious ahead of the report, reflecting concerns about divestiture-related revenue declines, ongoing payer-mix challenges, and the durability of cost-control measures. The guidance cut reinforced those concerns by indicating that management anticipates weaker profitability for the rest of the year.
Forward Outlook and Key Factors to Monitor
Community Health Systems (CYH) lowered its 2026 guidance, now expecting net operating revenues of $11.3 billion to $11.5 billion, adjusted EBITDA of $1.225 billion to $1.275 billion, and a net loss per share of $1.60 to $1.70. The previous outlook had called for revenue of $11.40 billion to $11.60 billion, adjusted EBITDA of $1.300 billion to $1.375 billion, and a loss per share of $1.10 to $1.25.
Several factors deserve attention in coming quarters. Same-store volume trends remain important, as underlying admissions and adjusted admissions continued to grow despite the revenue impact from divestitures. Payer mix is another key variable, given the margin pressure from shifts toward lower-reimbursement coverage. Specialist fee inflation and supplemental reimbursement program costs also warrant monitoring because of their direct effect on adjusted EBITDA. Finally, any further portfolio changes or debt-reduction steps could influence both the top line and balance-sheet strength. Management’s commentary on the upcoming conference call should provide more color on whether the same-store recovery can offset these headwinds. From what I see, the same-store momentum is worth watching closely.
Using AI Tools in My Research Process
I regularly use Tickeron’s AI Screener when reviewing earnings reports like this one. The tool lets me quickly filter healthcare stocks by technical patterns, fundamentals, and performance metrics, helping surface comparable names and signals that might otherwise take hours to identify manually. It has become a practical part of my workflow for putting individual company results into broader context.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CYH in +1.03% Uptrend, advancing for three consecutive days on October 26, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CYH advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CYH just turned positive on October 12, 2026. Looking at past instances where CYH's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
CYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where CYH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYH as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
CYH moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYH crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.288) is normal, around the industry mean (204.200). P/E Ratio (1.511) is within average values for comparable stocks, (19.451). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.498). Dividend Yield (0.352) settles around the average of (0.096) among similar stocks. P/S Ratio (0.034) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. CYH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of general acute care hospitals
Industry HospitalNursingManagement
Advertisement